



ESMO VIRTUAL PRECEPTORSHIP

**24-25 SEPTEMBER 2021** 

**Co-Chairs** 

Anthony T.C. Chan, Hong Kong Jean-Pascal Machiels, Belgium

# ESMO VIRTUAL PRECEPTORSHIP PROGRAMME HEAD & NECK CANCER

Multidisciplinary management, standards of care, therapeutic targets and future perspectives

#### 24-25 September 2021

**CO-CHAIRS:** Anthony T. C. Chan, Hong Kong

Jean-Pascal Machiels, Belgium

**SPEAKERS:** Melvin L. K. Chua, Singapore

Anil D'Cruz, India Lisa Licitra, Italy

Brigette Ma, Hong Kong Sandra Nuyts, Belgium Christian Simon, Switzerland

#### **LEARNING OBJECTIVES**

- To understand epidemiology, aetiology and molecular biology of nasopharyngeal cancer and squamous cell carcinoma of the head and neck (HNSCC)
- To understand multidisciplinary management and treatment of head and neck cancer
- To learn about advances in the treatment and novel targets in head and neck cancer
- To learn about management and treatment of salivary gland cancer

#### **ACCREDITATION**

The programme of this event has been accredited with **6 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For the future details please refer to esmo.org

#### **ACKNOWLEDGMENTS**

This event is supported by an unrestricted educational grant from



#### **ORGANISATION AND CONTACTS**

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland

Email: courses@esmo.org

www.esmo.org



### All timings are to be considered GMT+8 (Singapore Local Time)

## Friday, 24 September 2021

15:00-15:10 10'	Welcome and introduction	Anthony T. C. Chan, HK Jean-Pascal Machiels, BE
15:10-17:00 100'	SESSION 1 Nasopharyngeal cancer	Chair/Moderator: Anthony T. C. Chan, HK
30'	Management of localized disease	Melvin L. K. Chua, SG
30'	Management of metastatic disease and salvage treatment	Brigette Ma, HK
10'	Discussion	Faculty
16:20-16:30	Break	
30'	Participants clinical case discussion (3x10')	Faculty
17:00-18:25 85'	SESSION 2 Squamous cell carcinoma – part 1	Chair/Moderator: Jean-Pascal Machiels, BE
15'	Epidemiology, anatomy and work-up	Christian Simon, CH
30'	Indications and techniques of surgery for the primary treatment of HNSCC	Christian Simon, CH
30'	Indications and modalities of radiation or CRT for local and locoregional disease	Sandra Nuyts, BE
10'	Discussion	Faculty

## Saturday, 25 September 2021

•	•	
15:00-15:40 40'	SESSION 3 Squamous cell carcinoma – part 2	Chair/Moderator: Jean-Pascal Machiels, BE
30'	Oral cavity cancer in Asia: Risk factors, management and neck dissection	Anil D'Cruz, IN
10'	Discussion	Faculty
15:40-17:10 80'	SESSION 4 Precision medicine for head and neck cancer	Chair/Moderator: Anthony T. C. Chan, HK
30'	Relapsing HNSCC (salvage treatment, systemic treatment and immunotherapy)	Jean-Pascal Machiels, BE
10'	Discussion	Faculty
16:20-16:30	Break	
30'	Participants clinical case discussion (3x10')	Faculty
10'	Discussion	Faculty

17:10-17:50 40'	SESSION 5 Salivary gland cancer	Chair/Moderator: Jean-Pascal Machiels, BE
30'	Salivary gland cancer	Lisa Licitra, IT
10'	Discussion	Faculty
17:50-18:00 10'	Conclusion and farewell	Anthony T. C. Chan, HK Jean-Pascal Machiels, BE

Note: Each 10' minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion